[{"id":"2e85a5b8-b10e-4206-ac90-9608e25af12e","acronym":"SWOG S1609","url":"https://clinicaltrials.gov/study/NCT02834013","created_at":"2021-01-29T07:12:52.961Z","updated_at":"2025-02-25T16:36:45.708Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","source_id_and_acronym":"NCT02834013 - SWOG S1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 overexpression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 01/30/2017","start_date":" 01/30/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-06"},{"id":"569368a9-e762-49bc-b3b0-d10e7bc1381f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02390752","created_at":"2021-01-18T11:23:54.887Z","updated_at":"2025-02-25T16:58:46.439Z","phase":"Phase 1","brief_title":"Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...","source_id_and_acronym":"NCT02390752","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Turalio (pexidartinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 04/29/2015","start_date":" 04/29/2015","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-03"},{"id":"310e9d9a-b69c-4442-97f5-d4d4ad2729a2","acronym":"NCI-2018-00918","url":"https://clinicaltrials.gov/study/NCT03449108","created_at":"2022-07-22T15:57:20.497Z","updated_at":"2024-07-02T16:35:02.803Z","phase":"Phase 2","brief_title":"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas","source_id_and_acronym":"NCT03449108 - NCI-2018-00918","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • CD8 • CD28 • CD27","pipe":" | ","alterations":" CD8 expression • CD28 expression","tags":["HER-2 • CD8 • CD28 • CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 expression • CD28 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • LN-145 • LN-145-S1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/27/2018","start_date":" 04/27/2018","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-17"},{"id":"762b685b-f9ad-4a92-b22c-56def7ff1101","acronym":"","url":"https://clinicaltrials.gov/study/NCT06331104","created_at":"2024-03-26T14:38:14.768Z","updated_at":"2024-07-02T16:35:11.868Z","phase":"","brief_title":"Network Pharmacology Prediction: Mechanism Study of Puerarin in the Treatment of Giant Cell Tumors of Bone","source_id_and_acronym":"NCT06331104","lead_sponsor":"Changye Zou","biomarkers":" ER","pipe":" | ","alterations":" ER expression • CDKN1B expression","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER expression • CDKN1B expression"],"overall_status":"Completed","enrollment":" Enrollment 145","initiation":"Initiation: 06/14/2012","start_date":" 06/14/2012","primary_txt":" Primary completion: 08/31/2023","primary_completion_date":" 08/31/2023","study_txt":" Completion: 08/31/2023","study_completion_date":" 08/31/2023","last_update_posted":"2024-04-02"},{"id":"c7ed1f4f-3e44-4c7b-b076-cd42968023eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04952818","created_at":"2021-07-07T12:53:52.113Z","updated_at":"2024-07-02T16:36:28.282Z","phase":"","brief_title":"The Value of Preoperative Diagnosis and Prognostic Prediction Based on Radiomics of Giant Cell Tumor of Spine","source_id_and_acronym":"NCT04952818","lead_sponsor":"Peking University Third Hospital","biomarkers":" VEGFA","pipe":"","alterations":" ","tags":["VEGFA"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 01/01/2020","start_date":" 01/01/2020","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/01/2020","study_completion_date":" 03/01/2020","last_update_posted":"2021-07-07"},{"id":"00e1255f-7944-4ee8-a378-ddd0ceee33c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04002817","created_at":"2021-03-30T17:55:07.698Z","updated_at":"2024-07-02T16:36:30.748Z","phase":"","brief_title":"Giant Cell Tumor of the Bone in Young Patients","source_id_and_acronym":"NCT04002817","lead_sponsor":"Istituto Ortopedico Rizzoli","biomarkers":" H3-3A","pipe":"","alterations":" ","tags":["H3-3A"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 06/05/2019","start_date":" 06/05/2019","primary_txt":" Primary completion: 12/30/2019","primary_completion_date":" 12/30/2019","study_txt":" Completion: 06/30/2020","study_completion_date":" 06/30/2020","last_update_posted":"2021-05-04"},{"id":"ae04c4b0-5e58-41e5-a5a2-7672c264f891","acronym":"","url":"https://clinicaltrials.gov/study/NCT01643850","created_at":"2021-01-18T07:04:45.792Z","updated_at":"2024-07-02T16:36:36.582Z","phase":"Phase 2","brief_title":"MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)","source_id_and_acronym":"NCT01643850","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CSF1 • CD14","pipe":"","alterations":" ","tags":["CSF1 • CD14"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lacnotuzumab (MCS110)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 04/23/2012","start_date":" 04/23/2012","primary_txt":" Primary completion: 12/07/2017","primary_completion_date":" 12/07/2017","study_txt":" Completion: 12/21/2018","study_completion_date":" 12/21/2018","last_update_posted":"2021-01-05"},{"id":"776eb7f9-adf5-46d4-8cef-d2bc4c10c7d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03605199","created_at":"2023-06-15T16:08:15.111Z","updated_at":"2024-07-02T16:36:56.577Z","phase":"Phase 2","brief_title":"Denosumab in Subjects With Giant Cell Rich Tumors of Bone","source_id_and_acronym":"NCT03605199","lead_sponsor":"Leiden University Medical Center","biomarkers":" GCG","pipe":"","alterations":" ","tags":["GCG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Prolia (denosumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/18/2018","start_date":" 06/18/2018","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2019-08-26"},{"id":"d0720c37-2a12-40d4-ad50-cde72e0d168e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03259152","created_at":"2021-01-18T16:06:04.187Z","updated_at":"2024-07-02T16:37:18.509Z","phase":"Phase 3","brief_title":"Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone","source_id_and_acronym":"NCT03259152","lead_sponsor":"Hebei Medical University Third Hospital","biomarkers":" KEAP1 • COL1A1 • GAPDH • ACAN • TNFRSF11B","pipe":"","alterations":" ","tags":["KEAP1 • COL1A1 • GAPDH • ACAN • TNFRSF11B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Prolia (denosumab)"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 05/01/2019","primary_completion_date":" 05/01/2019","study_txt":" Completion: 05/01/2019","study_completion_date":" 05/01/2019","last_update_posted":"2017-08-24"}]